|
PSA
Greater Than 10.0 ng/ml
|
|
Gleason Score
|
Pathology Risk
|
Clinical
Stage
|
|
T1c
|
T2a
|
T2b
|
T2c
|
|
2-4
|
Confined
to Prostate
|
80
|
61-95
|
65
|
43-89
|
57
|
35-86
|
54
|
32-85
|
|
Spread to Prostate Capsule
|
20
|
5-39
|
35
|
11-57
|
43
|
14-65
|
46
|
15-68
|
|
Spread to Seminal Vesicles
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
|
Spread to Lymph Nodes
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
0
|
0-0
|
|
5-6
|
Confined
to Prostate
|
62
|
58-64
|
42
|
38-46
|
33
|
28-38
|
30
|
21-38
|
| |
Spread to Prostate Capsule
|
33
|
30-36
|
47
|
43-52
|
52
|
46-56
|
51
|
42-60
|
| |
Spread to Seminal Vesicles
|
4
|
3-5
|
6
|
4-8
|
8
|
5-11
|
6
|
2-12
|
| |
Spread to Lymph Nodes
|
2
|
1-3
|
4
|
3-7
|
8
|
5-12
|
13
|
6-22
|
|
3+4=7
|
Confined
to Prostate
|
37
|
32-42
|
20
|
17-24
|
14
|
11-17
|
11
|
7-17
|
|
Spread to Prostate Capsule
|
43
|
38-48
|
49
|
43-55
|
47
|
40-53
|
42
|
30-55
|
|
Spread to Seminal Vesicles
|
12
|
9-17
|
16
|
11-22
|
17
|
12-24
|
13
|
6-24
|
|
Spread to Lymph Nodes
|
8
|
5-11
|
14
|
9-21
|
22
|
15-30
|
33
|
18-49
|
|
4+3=7
|
Confined
to Prostate
|
27
|
21-34
|
14
|
10-18
|
9
|
6-13
|
7
|
4-12
|
| |
Spread to Prostate Capsule
|
51
|
44-59
|
55
|
46-64
|
50
|
40-60
|
43
|
29-59
|
| |
Spread to Seminal Vesicles
|
11
|
6-17
|
13
|
7-20
|
13
|
8-21
|
10
|
3-20
|
| |
Spread to Lymph Nodes
|
10
|
5-17
|
18
|
10-27
|
27
|
16-39
|
38
|
20-58
|
|
8-10
|
Confined
to Prostate
|
22
|
16-30
|
11
|
7-15
|
7
|
4-10
|
6
|
3-10
|
|
Spread to Prostate Capsule
|
50
|
42-59
|
52
|
41-62
|
46
|
36-59
|
41
|
27-57
|
|
Spread to Seminal Vesicles
|
17
|
10-25
|
19
|
12-29
|
19
|
12-29
|
15
|
5-28
|
|
Spread to Lymph Nodes
|
11
|
5-18
|
17
|
9-29
|
27
|
14-40
|
38
|
20-59
|
